Due to its unique dosage form, nab-sirolimus has a superior pharmacokinetics profile, higher tumour tissue drug exposure, stronger target cell inhibition, and better safety profile than other marketed mTOR inhibitors.218. Here, MTOR is linked to neoplasm.